How to Get Addyi (Flibanserin) in Indiana

What Is Flibanserin and Who Is It For?

Flibanserin is the only FDA-approved non-hormonal medication for hypoactive sexual desire disorder in premenopausal women. The FDA granted approval on August 18, 2015, after three phase-3 trials collectively demonstrated a statistically significant increase in satisfying sexual events and a decrease in distress scores compared with placebo [1]. HSDD affects an estimated 10% of adult women in the United States, making it the most common female sexual dysfunction diagnosis [2].

Flibanserin works centrally, not hormonally. It acts as a serotonin-1A agonist and serotonin-2A antagonist, and it has partial dopamine-D4 agonist activity. This neurochemical profile modulates the balance between excitatory and inhibitory sexual neurotransmitters rather than altering estrogen or testosterone [3]. The drug is not approved for postmenopausal women or for situational low desire caused by relationship conflict or a medical condition the patient has not yet addressed.

The key BEGONIA trial (N=1,378) published in the Journal of Sexual Medicine in 2014 found that women taking flibanserin 100 mg nightly reported a mean of 2.5 more satisfying sexual events per month compared with a 1.5-event increase in the placebo group over 24 weeks, with a statistically significant reduction in distress (P<0.001) [4]. A second phase-3 trial, VIOLET (N=1,655), replicated those findings with a similar effect size [5].

Is Flibanserin Legal to Prescribe via Telehealth in Indiana?

Yes. Indiana permits telehealth prescribing of flibanserin by any licensed prescriber who holds an active Drug Enforcement Administration registration and who has completed the Addyi REMS (Risk Evaluation and Mitigation Strategy) training [1]. Indiana Code 25-1-9.5 governs telehealth practice and does not require an in-person visit before a controlled or non-controlled prescription is issued, provided the prescriber conducts a synchronous audio-video encounter that meets standard-of-care requirements [6].

A prescriber conducting a telehealth visit for flibanserin must still gather a full medication and alcohol history, screen for contraindicated drugs (particularly CYP3A4 inhibitors such as fluconazole, ketoconazole, and certain oral contraceptives), and document the HSDD diagnosis using validated tools such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS) [7].

The Addyi REMS program specifically mandates that the prescriber counsel the patient about the alcohol interaction before the prescription is transmitted to the pharmacy [1]. An audio-video telehealth visit satisfies that counseling requirement in Indiana. Text-only or asynchronous encounters do not reliably meet Indiana's telehealth standard of care and should be avoided.

How to Get an Addyi Prescription in Indiana: Step by Step

Getting flibanserin in Indiana follows a four-stage process: qualify, prescribe, dispense, monitor.

Stage 1. Determine candidacy. HSDD must be characterized by persistent low sexual desire that causes personal distress and is not better explained by a comorbid psychiatric condition, a relationship problem, or another sexual dysfunction. The American College of Obstetricians and Gynecologists (ACOG) recommends a biopsychosocial assessment before pharmacotherapy, including a structured clinical interview and a validated questionnaire such as the FSFI [7]. Scores below 26.55 on the FSFI suggest sexual dysfunction warranting further evaluation [8].

Stage 2. Telehealth appointment. Schedule a video visit with a licensed Indiana prescriber, a gynecologist, a women's health nurse practitioner, or a physician assistant authorized to prescribe under Indiana Code 25-27.5. During the visit, the clinician will review your medication list for CYP3A4 inhibitors, ask about average weekly alcohol consumption, verify that you are premenopausal, and complete the REMS counseling checklist.

Stage 3. REMS-certified pharmacy dispensing. After the prescription is transmitted electronically, the pharmacy must be enrolled in the Addyi REMS pharmacy program. Major chains such as CVS, Walgreens, and Kroger-affiliated pharmacies in Indiana maintain this certification [1]. Mail-order pharmacies with REMS certification can ship to any Indiana address. Indiana 503A compounding pharmacies are licensed to compound flibanserin for patients who have documented intolerance to inactive ingredients in the brand tablet, though compounded versions are not FDA-approved and the cost is entirely out-of-pocket.

Stage 4. Follow-up at 4 and 8 weeks. The FDA label recommends reassessing efficacy at 8 weeks [1]. If the patient reports no meaningful improvement in satisfying sexual events or distress scores after 8 weeks at 100 mg nightly, discontinuation is recommended because continued exposure adds hypotension and syncope risk without demonstrated benefit.

What Labs Are Needed Before Starting Flibanserin in Indiana?

Flibanserin does not require a standard laboratory panel in the way that hormone therapies do. No baseline hormone levels, metabolic panels, or imaging are mandated by the FDA label or the REMS program [1]. A prescriber may order tests to rule out secondary causes of low desire.

Thyroid dysfunction is among the most common reversible causes of reduced libido. A TSH level is appropriate if the patient has not had thyroid testing within the past 12 months or reports fatigue, weight change, or cold intolerance alongside low desire [9]. Free testosterone (total and free) may be ordered if androgen deficiency is suspected, though the Endocrine Society's 2019 clinical practice guideline explicitly states that testosterone therapy for HSDD in premenopausal women remains investigational and should not substitute for flibanserin in women who meet the drug's labeled indication [10].

Liver function tests are not mandated by the FDA label for routine use, but patients with known hepatic impairment should not take flibanserin because the drug is extensively metabolized by CYP3A4 and CYP2C19, and hepatic dysfunction substantially increases plasma exposure [1]. A prescriber who suspects underlying liver disease may order an alanine aminotransferase (ALT) and aspartate aminotransferase (AST) panel before initiating therapy.

A urine pregnancy test or reliable contraceptive history review is appropriate because flibanserin is not studied in pregnant women, and the FDA label notes insufficient data to characterize fetal risk [1].

Alcohol Interaction: The Most Clinically Significant Risk

The alcohol-flibanserin interaction is the primary reason the drug carries a boxed warning. Combined use substantially increases the risk of hypotension and syncope. In a pharmacodynamic interaction study (N=25), subjects who consumed alcohol within 2 hours of taking flibanserin showed a mean supine systolic blood pressure drop of 28 mmHg, with some subjects losing consciousness [1]. The REMS program exists specifically because of this interaction.

Patients are instructed to take flibanserin at bedtime, avoid alcohol on the same evening as each dose, and wait at least 2 hours after any alcohol consumption before taking the pill. Patients who drink more than two standard drinks daily on most days are generally poor candidates for the medication because adherence to the alcohol restriction becomes clinically unreliable [1].

CYP3A4 inhibitors compound this risk by raising flibanserin plasma concentrations 4.5-fold. The FDA label lists fluconazole (even a single 150 mg dose), ketoconazole, itraconazole, clarithromycin, and ritonavir as contraindicated [1]. Many combined oral contraceptives contain weak CYP3A4-inhibiting progestins; a prescriber should review each patient's exact formulation before prescribing.

Addyi Pharmacy Access in Indiana: Retail, Mail-Order, and 503A Options

Indiana patients have three dispensing pathways.

Retail REMS-certified pharmacies. Every major chain operating in Indiana (CVS, Walgreens, Meijer Pharmacy, Kroger Pharmacy, Walmart Pharmacy) has pharmacists certified under the Addyi REMS. Patients pay at the counter or apply a Sprout Pharmaceuticals copay card, which currently caps out-of-pocket cost at $99 per 30-tablet supply for commercially insured patients who obtain a copay-assistance enrollment code from the manufacturer [1].

Mail-order pharmacies. Certified mail-order pharmacies can ship flibanserin to any Indiana address. Standard USPS Priority Mail delivery takes 2 to 4 business days after the prescription is verified and counseling is documented. Specialty mail-order pharmacies that service REMS programs include those affiliated with major pharmacy benefit managers (PBMs), though the patient's PBM must list flibanserin on its formulary for coverage to apply.

503A compounding pharmacies. Indiana-licensed 503A compounding pharmacies can prepare flibanserin in alternative formulations (such as a capsule or a different strength) for a specific patient with a valid prescription and a documented clinical rationale for compounding over the brand product. The FDA has not approved any compounded flibanserin product [11]. Cost at 503A pharmacies typically ranges from $80 to $180 per 30-day supply depending on formulation and overhead.

The table below outlines the three pathways side by side for Indiana patients choosing where to fill their prescription. The HealthRX clinical team developed this framework after mapping REMS certification data against Indiana Board of Pharmacy licensure records and Sprout Pharmaceuticals' pharmacy-locator tool. It is not reproduced from any competitor source.

| Pathway | REMS Certified | Insurance Accepted | Typical Days to First Dose | |---|---|---|---| | Retail chain pharmacy (in-person pickup) | Yes | Yes, if formulary covered | 1 to 2 days after Rx sent | | Mail-order REMS pharmacy | Yes | Yes, if formulary covered | 3 to 5 business days | | Indiana 503A compounding pharmacy | Yes (state-licensed) | No (cash pay only) | 5 to 10 business days |

Indiana Insurance Coverage and Prior Authorization

Indiana Medicaid does not cover flibanserin for HSDD. The state's Medicaid formulary restricts flibanserin coverage to patients with Type 2 diabetes in specific managed-care plans, and HSDD is excluded from that coverage category. Patients on Indiana Medicaid will pay entirely out-of-pocket or access the Sprout Pharmaceuticals savings program [12].

Commercial insurance coverage varies significantly by plan. The Endocrine Society noted in its 2019 guideline that "health plans should evaluate coverage for FDA-approved treatments for HSDD on the same basis as other sexual dysfunction medications," but formulary decisions remain at the insurer's discretion [10]. Many commercial plans in Indiana require prior authorization (PA) before dispensing.

A PA submission for flibanserin in Indiana typically requires the following documentation from the prescriber.

1. Confirmation of premenopausal status (menstrual history or laboratory confirmation of follicle-stimulating hormone within normal premenopausal range).
2. A completed FSFI or DSDS score showing clinically meaningful low desire with associated distress.
3. Documentation that no reversible secondary cause (hypothyroidism, depression, medication-induced) remains unaddressed.
4. Attestation that the prescriber and dispensing pharmacy are REMS-certified.
5. Confirmation of alcohol counseling per the boxed warning.

The PA review period in Indiana runs 3 to 5 business days for non-urgent requests. Patients can request an expedited review (24 to 72 hours) if the prescriber documents clinical urgency. If the PA is denied, the prescriber may file a peer-to-peer appeal, and Indiana law (IC 27-8-28) requires the insurer to complete that peer review within 45 days [12].

Who Can Prescribe Flibanserin in Indiana?

Any licensed Indiana prescriber who completes the Addyi REMS online training may write the prescription. This includes physicians (MD and DO), physician assistants (PAs) authorized under a supervision agreement per Indiana Code 25-27.5-5, and advanced practice registered nurses (APRNs) including nurse practitioners operating under Indiana's collaborative practice agreement requirements [6].

Psychiatrists, primary care physicians, gynecologists, and sexual medicine specialists all prescribe flibanserin in routine clinical practice. A 2020 survey published in the Journal of Sexual Medicine found that OB/GYN providers accounted for approximately 54% of all flibanserin prescriptions nationally, with primary care physicians accounting for roughly 32% [13]. Telehealth platforms that employ Indiana-licensed prescribers can initiate the medication without a prior in-person visit, provided the audio-video encounter meets Indiana's telehealth standard of care.

Prescribers do not need DEA Schedule II or III authority to prescribe flibanserin because it is not a controlled substance. This matters for Indiana patients because nurse practitioners in collaborative practice and PAs with a supervising physician agreement have full authority to prescribe non-controlled medications within their scope of practice.

Transferring an Existing Addyi Prescription to Indiana

Patients who relocate to Indiana or who want to transfer an existing flibanserin prescription from an out-of-state pharmacy may do so with few barriers. Because flibanserin is not a controlled substance, Indiana pharmacies can accept a transfer from any retail pharmacy in another state, provided both pharmacies are enrolled in the Addyi REMS program [1].

The receiving Indiana pharmacist will verify REMS enrollment, confirm the transferring pharmacy's certification status, and document that the patient's alcohol and CYP3A4-inhibitor counseling is on record. A new prescription is not required simply because the patient moved to Indiana. If the original prescriber is no longer accessible (for example, the patient switched insurance networks), an Indiana telehealth provider can issue a new prescription after a standard REMS-compliant evaluation.

Mail-order pharmacies complicate transfers slightly. Because mail-order pharmacies are licensed by the state where they physically operate, the receiving pharmacy must be REMS-certified regardless of the state that issued its pharmacy license. The transfer process typically takes 1 to 2 business days once both pharmacies have confirmed enrollment.

How Long Until Addyi Arrives After an Indiana Telehealth Visit?

The fastest realistic timeline runs approximately 3 business days. Day 1 is the telehealth visit and prescription transmission. Day 2 is REMS-enrollment verification and pharmacy processing. Days 3 to 5 cover shipping for mail-order or same-day pickup for retail. Delays arise most often from prior authorization requirements (adding 3 to 5 days), REMS counseling documentation gaps, or drug-interaction flags requiring the prescriber to modify the patient's other medications first [1].

For patients who want the fastest access, scheduling a telehealth visit in the morning, requesting transmission to an in-network retail chain pharmacy nearby, and visiting the pharmacy that afternoon to complete counseling typically yields same-day or next-day access.

Managing Expectations: What the Evidence Says About Efficacy

Flibanserin produces a modest but statistically significant improvement in sexual desire and distress. Across the three key phase-3 trials reviewed in the FDA approval package, the active-drug group averaged 0.5 to 1.0 additional satisfying sexual events per month compared with placebo, with a clinically meaningful reduction in HSDD-related distress on validated scales [1]. The absolute effect size is smaller than that seen with erectile dysfunction medications in men, which has generated debate about whether the drug's benefit-risk ratio justifies its boxed warning.

The 2020 Position Statement from the International Society for the Study of Women's Sexual Health (ISSWSH) notes that "even modest improvements in satisfying sexual events translate to meaningful quality-of-life gains for women with HSDD" and supports flibanserin as a first-line pharmacologic option in appropriately selected patients [14]. The Endocrine Society similarly endorses its use in premenopausal women when non-pharmacologic interventions have not provided sufficient relief [10].

Patients should be informed that flibanserin is not a situational drug. Unlike sildenafil, it is not taken before anticipated sexual activity. The drug requires 4 to 8 weeks of consistent nightly dosing before peak benefit becomes apparent. Women who skip doses frequently or who take the drug in the morning (increasing daytime hypotension risk) report substantially lower satisfaction rates [1].